Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines

Next Previous
Trial Profile

A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Glabellar lines
  • Focus Therapeutic Use
  • Sponsors Galderma; Q-Med

Most Recent Events

  • 21 Mar 2023 Results (from 3 studies NCT03736928,NCT03960957and An open-label extension study) assessing the effect of ABO on glabellar lines at rest presented at the American Academy of Dermatology annual Meeting 2023.
  • 31 May 2022 According to a Galderma media release, Pooled data from NCT03736928, Phase 2; NCT03960957, Phase 3; NCT03687736, Phase 4 will be presented at the upcoming International Master Course on Aging Science (IMCAS) World Congress 2022 in Paris from June 3-5, 2022
  • 25 Apr 2021 Results assessing efficacy and safety of AbobotulinumtoxinA for the treatment of Moderate-to-Severe Glabellar Lines presented at the American Academy of Dermatology Virtual Meeting Experience 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top